Business
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a
About this update from Gri Bio, Inc.
[{"type":"image","alt":"GRI Bio, Inc.","displaySize":"","headline":null,"caption":"GRI Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":298,"height":144,"url":"https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3hBFb_FKWGgnaU05oPTe8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMw--/https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c","width":298,"height":144},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/3hBFb_FKWGgnaU05oPTe8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMw--/https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c","width":298,"height":144}},"lazy":false},{"type":"text","content":"Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026","length":100,"tagName":"p"},{"type":"text","content":"Register for the event here","length":27,"tagName":"p"},{"type":"text","content":"LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026.","length":480,"tagName":"p"},{"type":"text","content":"Management will discuss the Company’s differentiated immune-modulating pipeline, including progress across its inflammatory, fibrotic and autoimmune disease programs.","length":166,"tagName":"p"},{"type":"text","content":"Click here to register for the event. A live webcast of the fireside chat will be accessible on the Events page under the Investors section of the Company’s website (gribio.com).","length":178,"tagName":"p"},{"type":"text","content":"About GRI Bio, Inc.","length":19,"tagName":"p"},{"type":"text","content":"GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease p...